[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Galectin Therapeutic (GALT)

Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Income Statement for [[ item.sessionDateDisplayLong ]]

Fiscal Year End Date: 12/31

(Values in U.S. thousands)
  12-2019 09-2019 06-2019 03-2019 12-2018
Operating Expenses 5,188 2,863 3,020 2,367 2,985
Operating Income -5,188 -2,863 -3,020 -2,367 -2,985
Interest Expense 22 22 21 22 80
Other Income 73 101 43 14 15
Pre-tax Income -5,137 -2,784 -2,998 -2,375 -3,050
Net Income Continuous -5,137 -2,784 -2,998 -2,375 -3,050
Net Income $-5,137 $-2,784 $-2,998 $-2,375 $-3,050
EPS Basic Total Ops -0.08 -0.05 -0.06 -0.20 -0.08
EPS Basic Continuous Ops -0.09 -0.05 -0.06 -0.05 -0.07
EPS Diluted Total Ops -0.08 -0.05 -0.06 -0.20 -0.08
EPS Diluted Continuous Ops -0.09 -0.05 -0.06 -0.05 -0.07
EBITDA(a) $-5,179 $-2,855 $-3,012 $-2,357 $-2,985
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.